SLU-PP-332: Sourcing, Documentation and Price
SLU-PP-332 is a synthetic pan-ERR agonist sold for laboratory research. This page covers its identifiers, the studies that characterise it, and what documentation a supplier should provide.
SLU-PP-332 is a synthetic small-molecule agonist of the estrogen-related receptors (ERRα, ERRβ and ERRγ), sold as a research chemical for laboratory use. It is also referred to in the literature as SLU-PP-332, and its close analogue SLU-PP-915 is frequently discussed alongside it as a second-generation pan-ERR agonist [1][2]. The evidence block for this page does not supply a CAS number, molecular formula, molecular weight or sequence for SLU-PP-332; those identifiers should be confirmed against the supplier's certificate of analysis rather than assumed from a catalogue listing. The compound is characterised analytically by liquid chromatography–high resolution tandem mass spectrometry (LC-HRMS/MS), and its in vitro metabolic transformation products have been prepared using human liver S9 fractions [1].
The pathway at the centre of the published work is estrogen-related receptor signalling — ERRα, ERRβ and ERRγ are orphan nuclear receptors that regulate genes involved in mitochondrial biogenesis, oxidative phosphorylation, fatty acid oxidation and the Krebs cycle [6].
Research Studies
SLU-PP-332 and ERRα/β/γ agonism in cell-based assays
SLU-PP-332 is described in the literature as a well-established exercise mimetic and a widely used chemical probe for ERR activation [2]. A comprehensive structure–activity relationship (SAR) analysis of the SLU-PP-332 scaffold integrated chemical synthesis, cell-based functional assays, downstream gene-expression profiling and additional characterisation, with the stated aim of clarifying the structural features that govern potency, efficacy, selectivity and drug-like properties [2]. That work is in vitro and cell-based; it does not establish effects in whole animals or in humans.
SLU-PP-332 and in vitro metabolism
SLU-PP-332 and SLU-PP-915 were characterised by LC-HRMS/MS, and in vitro metabolic transformation products of both compounds were prepared using human liver S9 fractions [1]. The stated rationale for that work was that ERR agonists are being investigated as exercise mimetics and were therefore considered potentially relevant to sports drug testing programmes [1]. This is an analytical and metabolic study; it reports on how the compounds behave in a liver-fraction preparation, not on physiological outcomes.
SLU-PP-332 and ERR targeting in myoblasts from inactive women
A pilot study enrolled twenty women undergoing hip arthroplasty for coxarthrosis and divided them into an active group (n = 10) and an inactive group (n = 10) based on self-reported physical activity [3]. The study evaluated ERR targeting in myoblasts isolated from the skeletal muscle of the inactive women, assessing metabolic and expression changes associated with ERR activation [3]. This is an ex vivo study using cells isolated from a specific clinical population — inactive women undergoing hip arthroplasty — and its findings should not be generalised to other populations or to whole-body effects.
SLU-PP-332 and metabolic syndrome in animal models
A synthetic ERR agonist has been reported to alleviate metabolic syndrome in animal models [7]. That work is animal-only and does not establish effects in humans. The evidence block does not provide the species, dose or outcome measures for that study, so those details should be read from the primary paper rather than inferred here.
SLU-PP-915 and aerobic exercise capacity
SLU-PP-915, an orally active ERR agonist, has been reported to enhance aerobic exercise capacity [6]. ERRs are described as essential for skeletal muscle adaptation to aerobic exercise and as promising targets for related research [6]. This finding is from animal work; the evidence block does not supply the species or the magnitude of the effect, and no human data are provided.
SLU-PP-332 and doping-control analysis
SLU-PP-332 is a small synthetic ERRα/β/γ agonist that has been analysed for in vitro metabolites for doping-control purposes [4]. The World Anti-Doping Agency prohibits the use of exercise mimetics and metabolic modulators in sports [4]. This is an analytical chemistry context; it does not report physiological effects.
ERR activation as an exercise-mimetic strategy: review evidence
A systematic review has examined the physiological, molecular and clinical evidence on pharmacological activation of ERRα/β/γ as an exercise mimetic [5]. Physical inactivity contributes to the development of chronic diseases, and ERR activation has been proposed as a molecular strategy to mimic exercise-induced benefits [5]. Reviews synthesise existing evidence; they do not generate new primary data, and the conclusions of any review are limited by the studies it includes.
SLU-PP-332 and comparison with SLU-PP-915
Both SLU-PP-332 and SLU-PP-915 are described as pan-ERR agonists with doping potential, and both were characterised by LC-HRMS/MS with in vitro metabolic transformation products prepared from human liver S9 fractions [1]. SLU-PP-915 is described separately as an orally active ERR agonist [6]. The table below summarises what the evidence block states about each compound; it does not compare potency, because the evidence block does not provide comparative potency data.
| Attribute | SLU-PP-332 | SLU-PP-915 |
|---|---|---|
| Class | Pan-ERR agonist (ERRα/β/γ) | Pan-ERR agonist (ERRα/β/γ) |
| Analytical characterisation | LC-HRMS/MS [1] | LC-HRMS/MS [1] |
| In vitro metabolism | Human liver S9 fractions [1] | Human liver S9 fractions [1] |
| Reported route | Not stated in evidence block | Orally active [6] |
| Reported model for exercise capacity | Not stated in evidence block | Animal model [6] |
| Human data | None in evidence block | None in evidence block |
SLU-PP-332 and documentation expectations
Because SLU-PP-332 is characterised by LC-HRMS/MS and its metabolites have been studied in human liver S9 fractions [1], a supplier's documentation package should include an identity confirmation consistent with that analytical approach. The evidence block does not specify a required purity threshold, a storage condition or a stability profile for SLU-PP-332; those parameters should be requested from the supplier and verified against the certificate of analysis. Where a catalogue lists a molecular formula or molecular weight, that value should be checked against the primary analytical literature rather than accepted from a secondary listing.
If you are reading this for personal health reasons
This material is sold for laboratory research only. We do not provide dosing or medical guidance, and nothing on this page is a recommendation for human use. Anyone considering a compound for themselves should speak to a licensed clinician.
Sources
- [1] In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential. https://europepmc.org/article/PMC/PMC12835572
- [2] Chemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor signaling. https://europepmc.org/article/PMC/PMC13112601
- [3] Targeting ERRs to counteract age-related muscle atrophy associated with physical inactivity: a pilot study. https://europepmc.org/article/PMC/PMC12277287
- [4] Analysis and Identification of In Vitro Metabolites of Exercise Mimetic SLU-PP-332 ERRα/β/γ Agonist for Doping-Control Purposes. https://pubmed.ncbi.nlm.nih.gov/41688415/
- [5] [Pharmacological Activation of ERRα/β/γ as an Exercise Mimetic: Potential Therapeutic Applications]. https://pubmed.ncbi.nlm.nih.gov/42024694/
- [6] An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity. https://pubmed.ncbi.nlm.nih.gov/41421047/
- [7] A Synthetic ERR Agonist Alleviates Metabolic Syndrome. https://europepmc.org/article/PMC/PMC10801787